Tumor heterogeneity-driven individualized therapy

Evangelos G Baltagiannis^{1

2}, Demosthenis E Ziogas^{1

3}, William C Cho⁴, Michail Mitsis^{2

5}, Dimitrios H Roukos^{1

2

6}

Affiliations

¹ Centre for Biosystems & Genome Network Medicine, Ioannina University, Ioannina, 45110, Greece.
² Department of Surgery, University Hospital of Ioannina, Ioannina, 45500, Greece.
³ Department of Surgery, General Hospital of Ioannina, Ioannina, 45445, Greece.
⁴ Department of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong Kong, 999077, China.
⁵ Cancer Biobank Centre, Ioannina University, Ioannina, 45110, Greece.
⁶ Department of Systems Biology, Biomedical Research Foundation of the Academy of Athens, Athens, 11527, Greece.

Editorial

Evangelos G Baltagiannis et al. Future Oncol. 2021 Jan.

. 2021 Jan;17(3):235-240.

doi: 10.2217/fon-2020-0915. Epub 2020 Dec 11.

Evangelos G Baltagiannis^{1

2}, Demosthenis E Ziogas^{1

3}, William C Cho⁴, Michail Mitsis^{2

5}, Dimitrios H Roukos^{1

2

6}

¹ Centre for Biosystems & Genome Network Medicine, Ioannina University, Ioannina, 45110, Greece.
² Department of Surgery, University Hospital of Ioannina, Ioannina, 45500, Greece.
³ Department of Surgery, General Hospital of Ioannina, Ioannina, 45445, Greece.
⁴ Department of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong Kong, 999077, China.
⁵ Cancer Biobank Centre, Ioannina University, Ioannina, 45110, Greece.
⁶ Department of Systems Biology, Biomedical Research Foundation of the Academy of Athens, Athens, 11527, Greece.

No abstract available

Keywords: combination therapy; intratumor variability; liquid biopsy; next-generation sequencing; predictive biomarker.

Publication types